CA2252696A1 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis Download PDF

Info

Publication number
CA2252696A1
CA2252696A1 CA002252696A CA2252696A CA2252696A1 CA 2252696 A1 CA2252696 A1 CA 2252696A1 CA 002252696 A CA002252696 A CA 002252696A CA 2252696 A CA2252696 A CA 2252696A CA 2252696 A1 CA2252696 A1 CA 2252696A1
Authority
CA
Canada
Prior art keywords
formula
fluorophenyl
compound
oxoazetidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002252696A
Other languages
English (en)
French (fr)
Inventor
Deirdre Mary Bernadette Hickey
Robert John Ife
Dashyant Dhanak
Colin J. Theobald
Colin Andrew Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Individual filed Critical Individual
Publication of CA2252696A1 publication Critical patent/CA2252696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002252696A 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis Abandoned CA2252696A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP9608646.7 1996-04-26
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
EP9623756.5 1996-11-15
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds
EP9625121.0 1996-12-03

Publications (1)

Publication Number Publication Date
CA2252696A1 true CA2252696A1 (en) 1997-11-06

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002252696A Abandoned CA2252696A1 (en) 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis

Country Status (17)

Country Link
EP (1) EP0915843A1 (no)
JP (1) JP2000509049A (no)
AR (1) AR006833A1 (no)
AU (1) AU2698697A (no)
BR (1) BR9709196A (no)
CA (1) CA2252696A1 (no)
CZ (1) CZ341098A3 (no)
HU (1) HUP9901359A3 (no)
ID (1) ID16660A (no)
IL (1) IL126696A0 (no)
MA (1) MA26426A1 (no)
NO (1) NO984939L (no)
NZ (1) NZ332476A (no)
PE (1) PE64398A1 (no)
PL (1) PL329530A1 (no)
TR (1) TR199802160T2 (no)
WO (1) WO1997041098A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686119B1 (en) 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
CN1275949C (zh) 2001-03-28 2006-09-20 先灵公司 2－吖丁啶酮中间体化合物的对映体选择性合成
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
CA2820408C (en) 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013000267A1 (zh) 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
KR20140059203A (ko) 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도
EP2736908A1 (en) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclic pyrimidone compounds
KR20150111356A (ko) 2013-01-25 2015-10-05 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
MX2015009633A (es) 2013-01-25 2015-11-30 Glaxosmithkline Ip Dev Ltd Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona.
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
JP2023500710A (ja) 2019-11-09 2023-01-10 シャンハイ エスアイエムアール バイオテクノロジー カンパニー リミテッド 三環式ジヒドロイミダゾピリミドン誘導体、その調製方法、その医薬組成物及び使用
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
CZ14294A3 (en) * 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
MY128261A (en) * 1992-10-27 2007-01-31 Merck Sharp & Dohme New substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5981252A (en) * 1993-06-25 1999-11-09 Smithkline Beecham Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
JP3613398B2 (ja) * 1993-10-06 2005-01-26 イコス コーポレイション 血小板活性化因子アセチルヒドロラーゼ
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AP9701007A0 (en) * 1994-12-22 1997-07-31 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis.
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
TR199701762T1 (xx) * 1995-07-01 1998-05-21 Smithkline Beecham P.L.C. Damar t�kanmas� tedavisi i�in azetidinon t�revleri.
JP2000505063A (ja) * 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物

Also Published As

Publication number Publication date
PE64398A1 (es) 1999-01-06
BR9709196A (pt) 1999-05-25
MA26426A1 (fr) 2004-12-20
CZ341098A3 (cs) 1999-03-17
NO984939L (no) 1998-12-23
HUP9901359A3 (en) 2000-03-28
HUP9901359A2 (hu) 1999-08-30
EP0915843A1 (en) 1999-05-19
JP2000509049A (ja) 2000-07-18
ID16660A (id) 1997-10-30
NZ332476A (en) 2000-06-23
IL126696A0 (en) 1999-08-17
NO984939D0 (no) 1998-10-23
AU2698697A (en) 1997-11-19
AR006833A1 (es) 1999-09-29
TR199802160T2 (xx) 1999-04-21
WO1997041098A1 (en) 1997-11-06
PL329530A1 (en) 1999-03-29

Similar Documents

Publication Publication Date Title
CA2252696A1 (en) Azetidinone derivatives for the treatment of atherosclerosis
US6232338B1 (en) 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
DE69911980T2 (de) Pyrimidinonderivate zur behandlung von atheroscleros
AU704407B2 (en) Substituted azetidin-2-ones for treatment of atherosclerosis
US6071899A (en) Azetidinone derivatives for the treatment of atherosclerosis
JP2005533757A (ja) アテローム性動脈硬化症の治療においてｌｐ−ｐｌａ２阻害剤として用いるためのｎ−置換ピリジノンおよびピリミジノン誘導体
US5561227A (en) Process for the stereospecific synthesis of azetidinones
JP2005532292A (ja) 新規化合物
JP2005513012A (ja) Ｌｐ−ＰＬＡ２阻害剤としてのピリドン、ピリダゾンおよびトリアジノン誘導体
WO1997021676A1 (en) Azetidinone compounds for the treatment of atherosclerosis
WO1997021675A1 (en) Monocyclic beta-lactame derivatives for treatment of atherosclerosis
JPS6284082A (ja) ２−オキソ−１−〔〔（置換スルホニル）アミノ〕カルボニル〕アゼチジン類
CA2225627A1 (en) Azetidinone derivatives for the treatment of atherosclerosis
JP2000509063A (ja) アテローム性動脈硬化症の治療用アゼチジノン誘導体
US5461162A (en) Process of synthesizing n-acyl auxiliaries
IE842848L (en) Producing penems
US4382089A (en) Antibacterial amide compounds, compositions thereof and methods of using them
US4427586A (en) 2-Oxoazetidine derivatives and production thereof
US5731431A (en) Process for preparing 4-substituted azetidinone derivatives
JP3790564B2 (ja) シクロヘキサン誘導体、その製造法および疾患の治療におけるその使用
JPS63188662A (ja) 新規なβ−ラクタム誘導体の製造方法
KR20000065040A (ko) 아테롬성동맥경화증치료를위한아제티디논유도체
US4192801A (en) Novel phosphorane intermediates for use in preparing penem antibiotics
MXPA98008924A (en) Azetidinone derivatives for deeterosclero treatment
JPH0316357B2 (no)

Legal Events

Date Code Title Description
FZDE Discontinued